Please provide your email address to receive an email when new articles are posted on . Lirentelimab was safe and effective in the long-term treatment of patients with eosinophilic gastritis and/or ...
Eosinophilic gastritis and duodenitis are characterized by gastrointestinal mucosal eosinophilia, chronic symptoms, impaired quality of life, and a lack of adequate treatments. Mast-cell activity may ...
REDWOOD CITY, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback